News & Events

In this section

Instem Chosen by SRI International as New Preclinical System Provider

SRI Purchases Provantis Preclinical SaaS to Meet Needs of Growing Biosciences Operations

CONSHOHOCKEN, PA - (BUSINESS WIRE) – November 30, 2011 – Instem, a leading provider of early development software applications, announced today that SRI International (SRI) has selected the Provantis® Preclinical software solution suite to support their preclinical research and development.

Headquartered in Silicon Valley, and celebrating its 65th anniversary this year, SRI has been providing industry leaders, emerging companies, and government agencies with a broad range of pharmaceutical discovery and development capabilities for decades.

SRI’s Biosciences Division is a unique organization of approximately 270 people taking chemical and biological research programs from Idea to IND®— from initial discoveries to investigational new drug applications to start human clinical trials.

Key Facts

  • SRI selected integrated Provantis General Toxicology, Pathology, Clinical Pathology and Reproductive Toxicology modules
  • SRI to use SaaS delivery model from Instem’s U.S.-based data center, which supports both GLP and non-GLP study environments
  • Provantis selected for functionality, ease of use and reporting capabilities
  • Provantis to help increase capabilities for SRI, supporting continued growth as seen in recent contract wins from the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of Mental Health totaling nearly $190 million
  • Instem providing validation services on project

“We are honored that SRI has selected Instem as part of their system integration strategy,” said Shawn MacInnis, Sales Executive at Instem. “In addition to the proven functionality of our software, our demonstrated experience in managing a market-leading SaaS delivery model will benefit SRI.”

“SRI has been conducting toxicology studies compliant with FDA Good Laboratory Practice (GLP) regulations since their inception in 1978,” said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI’s Biosciences Division. “We have until recently used multiple data capture systems and have grown to the point where they were no longer meeting all of our needs.  Our team evaluated a number of leading products and selected Provantis® as the system that could best support our objectives.”

SRI is joining other leading organizations and government agencies by accessing Instem solutions from a secure centralized data center that meets the highest standards for reliability, security and redundancy and is managed by experienced staff 365 days a year.

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

Meeting clients at the intersection of investment & return™.

Press Contacts:

Gary Mitchell (US HQ)
Tel: 610-941-0990

Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600